-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$7.00677.78% Upside
Xilio Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. has been rated by research analysts at Chardan Capital in the past 90 days.